BIOPHYTIS SA-ADR (BPTS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BPTS • US09076G2030

8.22 USD
-1.48 (-15.28%)
At close: Apr 25, 2024
7.92 USD
-0.3 (-3.65%)
After Hours: 4/25/2024, 8:00:01 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to BPTS. BPTS was compared to 524 industry peers in the Biotechnology industry. Both the profitability and financial health of BPTS have multiple concerns. BPTS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • BPTS had negative earnings in the past year.
  • BPTS had a negative operating cash flow in the past year.
  • In the past 5 years BPTS always reported negative net income.
  • BPTS had a negative operating cash flow in each of the past 5 years.
BPTS Yearly Net Income VS EBIT VS OCF VS FCFBPTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -134.02%, BPTS is not doing good in the industry: 84.47% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -134.02%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BPTS Yearly ROA, ROE, ROICBPTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BPTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BPTS Yearly Profit, Operating, Gross MarginsBPTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

  • BPTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BPTS Yearly Shares OutstandingBPTS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M
BPTS Yearly Total Debt VS Total AssetsBPTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

  • BPTS has an Altman-Z score of -2.85. This is a bad value and indicates that BPTS is not financially healthy and even has some risk of bankruptcy.
  • BPTS's Altman-Z score of -2.85 is in line compared to the rest of the industry. BPTS outperforms 45.05% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.85
ROIC/WACCN/A
WACCN/A
BPTS Yearly LT Debt VS Equity VS FCFBPTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.81 indicates that BPTS may have some problems paying its short term obligations.
  • BPTS has a worse Current ratio (0.81) than 91.64% of its industry peers.
  • A Quick Ratio of 0.81 indicates that BPTS may have some problems paying its short term obligations.
  • BPTS has a Quick ratio of 0.81. This is amonst the worse of the industry: BPTS underperforms 91.13% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.81
BPTS Yearly Current Assets VS Current LiabilitesBPTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

  • BPTS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.64%, which is quite impressive.
EPS 1Y (TTM)63.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by 0.00% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-133.33%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BPTS Yearly Revenue VS EstimatesBPTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2024 10M 20M 30M 40M
BPTS Yearly EPS VS EstimatesBPTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BPTS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BPTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BPTS Price Earnings VS Forward Price EarningsBPTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BPTS Per share dataBPTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for BPTS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOPHYTIS SA-ADR

NASDAQ:BPTS (4/25/2024, 8:00:01 PM)

After market: 7.92 -0.3 (-3.65%)

8.22

-1.48 (-15.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15
Earnings (Next)09-25
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap94.20M
Revenue(TTM)N/A
Net Income(TTM)-19.58M
Analysts37.5
Price Target0.38 (-95.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-21.7%
PT rev (3m)-39.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-217.58%
EPS NY rev (3m)-108.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-17.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.8
EYN/A
EPS(NY)-3.52
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS0
BVpS-0.31
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -134.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.81
Altman-Z -2.85
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)55.71%
Cap/Depr(5y)70.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-133.33%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.85%
EBIT Next 3Y15.87%
EBIT Next 5YN/A
FCF growth 1Y18.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.89%
OCF growth 3YN/A
OCF growth 5YN/A

BIOPHYTIS SA-ADR / BPTS FAQ

What is the fundamental rating for BPTS stock?

ChartMill assigns a fundamental rating of 0 / 10 to BPTS.


Can you provide the valuation status for BIOPHYTIS SA-ADR?

ChartMill assigns a valuation rating of 0 / 10 to BIOPHYTIS SA-ADR (BPTS). This can be considered as Overvalued.


How profitable is BIOPHYTIS SA-ADR (BPTS) stock?

BIOPHYTIS SA-ADR (BPTS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for BIOPHYTIS SA-ADR?

The Earnings per Share (EPS) of BIOPHYTIS SA-ADR (BPTS) is expected to decline by -133.33% in the next year.